Innoviva Financial Statements
NASDAQ: INVAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Innoviva revenue and earnings
In fiscal 2025, Innoviva generated $411.3 million in revenue, up 14.7% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $271.2 million (+1059.2% year over year), for a net margin of 65.9% versus a median of 66.5% in the prior 5 years. Gross margin was 74.8% (down from 82.6%) and operating margin 39.8%.
Diluted earnings per share came in at $3.30, up from $0.36. Over the last 5 fiscal years, INVA's revenue has grown at a 4.1% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Innoviva income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 411.33M | 358.71M | 310.46M | 331.34M | 391.87M | 336.79M | 261.02M | 261.00M | 217.22M | 133.57M |
| Revenue growth (YoY) | +14.67% | +15.54% | -6.30% | -15.45% | +16.35% | +29.03% | +0.00% | +20.16% | +62.63% | +147.58% |
| Gross Profit | 307.67M | 296.21M | 246.04M | — | — | — | — | — | — | — |
| Operating Expenses | 143.92M | 129.34M | 132.15M | — | 16.76M | 15.67M | 14.66M | 22.75M | 33.61M | 24.58M |
| Research & Development | 30.60M | 13.65M | 33.92M | 41.43M | 576.00K | 1.79M | 0 | 0 | 1.35M | 1.39M |
| Selling, General & Admin | 113.32M | 115.69M | 98.23M | 63.54M | 16.19M | 13.88M | — | — | — | — |
| Operating Income | 163.75M | 166.87M | 113.89M | — | 375.10M | 321.12M | 246.36M | 238.25M | 183.60M | 108.99M |
| Interest Expense | 16.70M | 22.21M | 19.16M | 15.79M | 19.07M | 18.33M | 18.66M | 23.95M | 43.60M | 52.42M |
| Other Income (Expense) | -2.86M | -3.00M | -4.97M | -3.37M | -3.63M | -348.00K | -345.00K | -5.70M | -7.04M | 2.48M |
| Pretax Income | 326.86M | 37.39M | 194.10M | 286.95M | 445.28M | 354.25M | 232.90M | 210.25M | 134.28M | 59.63M |
| Income Tax | 55.70M | 14.00M | 14.38M | 66.69M | 76.44M | 60.43M | 41.90M | -196.07M | 4.00K | 95.00K |
| Net Income | 271.17M | 23.39M | 179.72M | 220.26M | 368.84M | 293.81M | 190.99M | 406.33M | 134.27M | 59.54M |
| Net Income growth (YoY) | +1059.22% | -86.98% | -18.41% | -40.28% | +25.53% | +53.83% | -53.00% | +202.62% | +125.53% | — |
| EPS (Basic) | 4.02 | 0.37 | 2.75 | 3.07 | 3.24 | 2.21 | 1.55 | 3.92 | 1.25 | 0.54 |
| EPS (Diluted) | 3.30 | 0.36 | 2.20 | 2.37 | 2.87 | 2.02 | 1.43 | 3.53 | 1.17 | 0.53 |
| Shares Outstanding (Basic) | 67.39M | 62.73M | 65.44M | 69.64M | 82.06M | 101.32M | 101.15M | 100.85M | 106.94M | 110.28M |
| Shares Outstanding (Diluted) | 84.76M | 74.19M | 86.88M | 95.25M | 94.31M | 113.55M | 113.41M | 113.41M | 119.87M | 123.23M |
| EBITDA | — | — | — | — | 388.94M | 334.96M | 260.23M | 252.12M | 197.59M | 122.94M |
| Gross Margin | 74.80% | 82.58% | 79.25% | — | — | — | — | — | — | — |
| Operating Margin | 39.81% | 46.52% | 36.68% | — | 95.72% | 95.35% | 94.39% | 91.28% | 84.53% | 81.60% |
| Net Margin | 65.92% | 6.52% | 57.89% | 66.48% | 94.12% | 87.24% | 73.17% | 155.68% | 61.81% | 44.57% |
This table shows 10 annual periods of Innoviva's income statement, from FY 2025 back to FY 2016, across 19 line items including revenue, gross profit, operating expenses. Values in USD; B = billions, M = millions. Fiscal periods follow INVA's reporting calendar. What is a income statement?